Why evaluate MDR1 receptor affinity in CNS pharmacokinetic assays?

The pharmacological implications in blood-brain barrier permeability assays. Drug delivery to the brain is a challenging evaluation to consider during novel compounds discovery stages to study central nervous pharmacokinetics in…

Continuar leyendo Why evaluate MDR1 receptor affinity in CNS pharmacokinetic assays?

BioPrintIA

  • Autor de la entrada:
  • Categoría de la entrada:NEWS

ReadyCell collaborates in the BioPrintIA project as a specialized partner in the biotechnology sector. BioPrintIA is a subsidised R&D project that develops a next-generation medical device based on artificial intelligence,…

Continuar leyendo BioPrintIA

Business Developer

  • Autor de la entrada:
  • Categoría de la entrada:NEWS

Readycell es una empresa biotecnológica de Barcelona que desarrolla, implementa y comercializa kits de base celular. Nos encontramos actualmente en una fase de expansión y consolidación y queremos incorporar en…

Continuar leyendo Business Developer

Pharmacology 2020 Event

  • Autor de la entrada:
  • Categoría de la entrada:NEWS

ReadyCell actively interacts with the Drug Discovery community, introducing cell-based in vitro systems and easing novel compounds’ preclinical development.

Continuar leyendo Pharmacology 2020 Event